CB-103
Sources
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03422679
CB-103 (pan-NOTCH inhibitor): Hanna GJ et al. Cancer Res Commun 2023, doi 10.1158/2767-9764.CRC-23-0333 (PMC10501326; publication not re-opened this run) and registry NCT03422679 (terminated for business reasons, n 79, no dose-limiting toxicities in any cohort, results posted 01.16.2024). No efficacy figure from this source is used.
Brief source A26
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03422679
A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05774899
A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)
ClinicalTrials.gov API v2 record, retrieved 2026-11-07